The potential of monoclonal antibodies for colorectal cancer therapy-Reference-Cited by-同舟云学术

The potential of monoclonal antibodies for colorectal cancer therapy

Published:2023-08-21 Issue:9 Volume:40 Page:
ISSN:1559-131X
Container-title:Medical Oncology
language:en
Short-container-title:Med Oncol

Author:

Heidari Fatemeh,Madadi Soheil,Alizadeh Neda,Alimardani Mohammad Hossein,Safari Armin,Armand Mohammad Hossein,Pishgahzadeh Elahe,Soleimani Meysam^ORCID

Funder

Vice Chancellor for Research and Technology, Hamadan University of Medical Sciences

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,Hematology,General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s12032-023-02151-1.pdf

Reference100 articles.

1. Siegel RL, Miller KD, Goding Sauer A, Fedewa SA, Butterly LF, Anderson JC, et al. Colorectal cancer statistics. CA Cancer J Clin. 2020;70(3):145–64 (PubMed PMID: 32133645. Epub 2020/03/07. eng).

2. Sinicrope FA. Increasing incidence of early-onset colorectal cancer. N Engl J Med. 2022;386(16):1547–58 (PubMed PMID: 35443109. Epub 2022/04/21. eng).

3. Su J, Liang H, Yao W, Wang N, Zhang S, Yan X, et al. MiR-143 and MiR-145 regulate IGF1R to suppress cell proliferation in colorectal cancer. PLoS ONE. 2014;9(12):114420 (PubMed PMID: 25474488. Pubmed Central PMCID: PMC4256231. Epub 2014/12/05. eng).

4. Haggar FA, Boushey RP. Colorectal cancer epidemiology: incidence, mortality, survival, and risk factors. Clin Colon Rectal Surg. 2009;22(4):191–7 (PubMed PMID: 21037809. Pubmed Central PMCID: PMC2796096. Epub 2010/11/03. eng).

5. Soleimani M, Mahnam K, Mirmohammad-Sadeghi H, Sadeghi-Aliabadi H, Jahanian-Najafabadi A. Theoretical design of a new chimeric protein for the treatment of breast cancer. Res Pharm Sci. 2016;11(3):187–99 (PubMed PMID: 27499788. Pubmed Central PMCID: PMC4962299. Epub 2016/08/09. eng).